About Laverock Therapeutics
Laverock Therapeutics is a company based in Stevenage (United Kingdom) founded in 2021. Laverock Therapeutics has raised $66.78 million across 3 funding rounds from investors including Lilly, Mercia and Maven Capital Partners. The company has 6 employees as of December 31, 2022. Laverock Therapeutics operates in a competitive market with competitors including Senti Biosciences, Caribou Biosciences, Sana Biotechnology, Immunocore and Semma Therapeutics, among others.
- Headquarter Stevenage, United Kingdom
- Employees 6 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Laverock Therapeutics Limited
- Date of Incorporation 13 Jul, 2021
- Jurisdiction ROMSEY, ENGLAND
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$66.78 M (USD)
in 3 rounds
-
Latest Funding Round
$27.5 M (USD), Seed
Jun 30, 2025
-
Investors
Lilly
& 8 more
-
Employee Count
6
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Laverock Therapeutics
Unlock access to complete
Funding Insights of Laverock Therapeutics
Laverock Therapeutics has successfully raised a total of $66.78M across 3 strategic funding rounds. The most recent funding activity was a Seed round of $27.5 million completed in June 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Laverock Therapeutics
Laverock Therapeutics has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Lilly, Mercia and Maven Capital Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
UK venture capital investments are managed by Calculus Capital.
|
Locked | Locked | Locked | |
|
Multiple sectors are targeted for private equity investments.
|
Locked | Locked | Locked | |
|
Early-stage innovations are funded by UKI2S across key sectors.
|
Locked | Locked | Locked |
Investor details for Laverock Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Laverock Therapeutics
Investment portfolio details for Laverock Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Laverock Therapeutics
Detailed financials for Laverock Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Laverock Therapeutics Comparisons
Peer comparison for Laverock Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Laverock Therapeutics
Laverock Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Senti Biosciences, Caribou Biosciences, Sana Biotechnology, Immunocore and Semma Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Cell-based therapies for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Provider of cell therapies to treat cancer and hematologic conditions
|
|
| Locked | Locked | Locked |
Genetically engineered cell therapies are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer
|
|
| Locked | Locked | Locked |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment
|
|
| Locked | Locked | Locked |
Therapeutics for diabetes and obesity treatment are developed.
|
Detailed competitors of Laverock Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Laverock Therapeutics
Complete news archive for Laverock Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Laverock Therapeutics
Laverock Therapeutics was founded in 2021 and raised its 1st funding round 1 year after it was founded.
Laverock Therapeutics is headquartered in Stevenage, United Kingdom. It is registered at Stevenage, Hertfordshire, United Kingdom.
David Venables is the current CEO of Laverock Therapeutics.
Laverock Therapeutics is a funded company, having raised a total of $66.78M across 3 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Laverock Therapeutics is 6.
Laverock Therapeutics was founded in 2021 in Stevenage, United Kingdom, within the biotechnology sector. Programmable cell therapies are engineered through gene editing induced gene silencing (GEiGS) technology and an associated computational platform. Induced pluripotent stem cell (iPSC)-derived therapies are created for therapeutic applications, with operations focused on advancing cell-based treatments in the region.
Laverock Therapeutics's top competitors include Immunocore, Achilles Therapeutics and Autolus.
Laverock Therapeutics has 9 investors. Key investors include Lilly, Mercia, Maven Capital Partners, Calculus Capital, and UKI2S.